glp 1 diabetes treatment The Landscape Of GLP-1 Receptor Agonists In And Obesity GLP-1 and Weight Loss: The

Current Developments in Nutrition

Michael Palladinetti, global head of business development and licensing at Sanofi, told delegates attending Bio Europe Spring in Barcelona, Spain last week that history has shown us time and time again that no one has the monopoly on the next wave of innovation. Citing the recent GLP-1 wave, Palladinetti said the industry has a bit of fear of missing out (FOMO) and paid kudos to Lily and Novo for staying in the space. He added how innovation is also very difficult and that industry players need to have a broad view. Both firms are pioneers in the diabetes space, having launched their own versions of insulin over 100 years ago

Exogenous taurine supplementation however, has shown some promising results on increasing time to fatigue during exhaustive exercise by up to 50% in rodents, and time to VO 2max in men [7981]

29 Patent Data is a Defensive Tool : Track the exclusivity stack to avoid infringing on delivery device and dosing regimen patents that extend far beyond 2031

Int J Pharm Res Allied Sci